388 related articles for article (PubMed ID: 25648700)
1. The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2.
Bannister ML; Thomas NL; Sikkel MB; Mukherjee S; Maxwell C; MacLeod KT; George CH; Williams AJ
Circ Res; 2015 Apr; 116(8):1324-35. PubMed ID: 25648700
[TBL] [Abstract][Full Text] [Related]
2. RYR2 Channel Inhibition Is the Principal Mechanism of Flecainide Action in CPVT.
Kryshtal DO; Blackwell DJ; Egly CL; Smith AN; Batiste SM; Johnston JN; Laver DR; Knollmann BC
Circ Res; 2021 Feb; 128(3):321-331. PubMed ID: 33297863
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
Hwang HS; Hasdemir C; Laver D; Mehra D; Turhan K; Faggioni M; Yin H; Knollmann BC
Circ Arrhythm Electrophysiol; 2011 Apr; 4(2):128-35. PubMed ID: 21270101
[TBL] [Abstract][Full Text] [Related]
4. Effect of flecainide derivatives on sarcoplasmic reticulum calcium release suggests a lack of direct action on the cardiac ryanodine receptor.
Bannister ML; Alvarez-Laviada A; Thomas NL; Mason SA; Coleman S; du Plessis CL; Moran AT; Neill-Hall D; Osman H; Bagley MC; MacLeod KT; George CH; Williams AJ
Br J Pharmacol; 2016 Aug; 173(15):2446-59. PubMed ID: 27237957
[TBL] [Abstract][Full Text] [Related]
5. Flecainide Paradoxically Activates Cardiac Ryanodine Receptor Channels under Low Activity Conditions: A Potential Pro-Arrhythmic Action.
Salvage SC; Gallant EM; Fraser JA; Huang CL; Dulhunty AF
Cells; 2021 Aug; 10(8):. PubMed ID: 34440870
[TBL] [Abstract][Full Text] [Related]
6. The direct actions of flecainide on the human cardiac ryanodine receptor: keeping open the debate on the mechanism of action of local anesthetics in CPVT.
Smith GL; MacQuaide N
Circ Res; 2015 Apr; 116(8):1284-6. PubMed ID: 25858058
[No Abstract] [Full Text] [Related]
7. Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity.
Liu N; Denegri M; Ruan Y; Avelino-Cruz JE; Perissi A; Negri S; Napolitano C; Coetzee WA; Boyden PA; Priori SG
Circ Res; 2011 Jul; 109(3):291-5. PubMed ID: 21680895
[TBL] [Abstract][Full Text] [Related]
8. Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass.
Hilliard FA; Steele DS; Laver D; Yang Z; Le Marchand SJ; Chopra N; Piston DW; Huke S; Knollmann BC
J Mol Cell Cardiol; 2010 Feb; 48(2):293-301. PubMed ID: 19835880
[TBL] [Abstract][Full Text] [Related]
9. How does flecainide impact RyR2 channel function?
Salvage SC; Huang CL; Fraser JA; Dulhunty AF
J Gen Physiol; 2022 Sep; 154(9):. PubMed ID: 35713932
[TBL] [Abstract][Full Text] [Related]
10. Channel Activity of Cardiac Ryanodine Receptors (RyR2) Determines Potency and Efficacy of Flecainide and R-Propafenone against Arrhythmogenic Calcium Waves in Ventricular Cardiomyocytes.
Savio-Galimberti E; Knollmann BC
PLoS One; 2015; 10(6):e0131179. PubMed ID: 26121139
[TBL] [Abstract][Full Text] [Related]
11. Na+-dependent SR Ca2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation.
Sedej S; Heinzel FR; Walther S; Dybkova N; Wakula P; Groborz J; Gronau P; Maier LS; Vos MA; Lai FA; Napolitano C; Priori SG; Kockskämper J; Pieske B
Cardiovasc Res; 2010 Jul; 87(1):50-9. PubMed ID: 20080988
[TBL] [Abstract][Full Text] [Related]
12. Moving in the right direction: elucidating the mechanisms of interaction between flecainide and the cardiac ryanodine receptor.
Bannister ML; MacLeod KT; George CH
Br J Pharmacol; 2022 Jun; 179(11):2558-2563. PubMed ID: 34698387
[TBL] [Abstract][Full Text] [Related]
13. Insights on the mechanism of flecainide in catecholaminergic polymorphic ventricular tachycardia.
Davidson R; Medeiros M
J Med Life; 2023 Aug; 16(8):1294-1296. PubMed ID: 38024821
[TBL] [Abstract][Full Text] [Related]
14. Prevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation.
Alcalai R; Wakimoto H; Arad M; Planer D; Konno T; Wang L; Seidman JG; Seidman CE; Berul CI
J Cardiovasc Electrophysiol; 2011 Mar; 22(3):316-24. PubMed ID: 20807279
[TBL] [Abstract][Full Text] [Related]
15. Ca2+-dependent modulation of voltage-gated myocyte sodium channels.
Salvage SC; Habib ZF; Matthews HR; Jackson AP; Huang CL
Biochem Soc Trans; 2021 Nov; 49(5):1941-1961. PubMed ID: 34643236
[TBL] [Abstract][Full Text] [Related]
16. EL20, a potent antiarrhythmic compound, selectively inhibits calmodulin-deficient ryanodine receptor type 2.
Klipp RC; Li N; Wang Q; Word TA; Sibrian-Vazquez M; Strongin RM; Wehrens XHT; Abramson JJ
Heart Rhythm; 2018 Apr; 15(4):578-586. PubMed ID: 29248564
[TBL] [Abstract][Full Text] [Related]
17. A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses.
Preininger MK; Jha R; Maxwell JT; Wu Q; Singh M; Wang B; Dalal A; Mceachin ZT; Rossoll W; Hales CM; Fischbach PS; Wagner MB; Xu C
Dis Model Mech; 2016 Sep; 9(9):927-39. PubMed ID: 27491078
[TBL] [Abstract][Full Text] [Related]
18. In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia.
Yang PC; Moreno JD; Miyake CY; Vaughn-Behrens SB; Jeng MT; Grandi E; Wehrens XH; Noskov SY; Clancy CE
J Physiol; 2016 Feb; 594(3):567-93. PubMed ID: 26515697
[TBL] [Abstract][Full Text] [Related]
19. Flecainide exerts paradoxical effects on sodium currents and atrial arrhythmia in murine RyR2-P2328S hearts.
Salvage SC; King JH; Chandrasekharan KH; Jafferji DI; Guzadhur L; Matthews HR; Huang CL; Fraser JA
Acta Physiol (Oxf); 2015 Jul; 214(3):361-75. PubMed ID: 25850710
[TBL] [Abstract][Full Text] [Related]
20. Targeting intracellular calcium cycling in catecholaminergic polymorphic ventricular tachycardia: a theoretical investigation.
Sung RJ; Lo CP; Hsiao PY; Tien HC
Am J Physiol Heart Circ Physiol; 2011 Oct; 301(4):H1625-38. PubMed ID: 21742998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
